CD8 Veto


Greffex Veto Vector GreCD8

Presently, transplant rejection is prevented by the induction of a general immune suppression in the organ recipient. Therapy regiments are being used, in which patients are held in a lifelong immune suppressive therapy. As a result, recipients who are immune compromised are suffering from impaired natural defenses against infectious threats and malignant growths. Nevertheless, organs are not fully protected. They are continuously lost to flair-ups of chronic rejection processes resulting in significant attrition rates.

Greffex has developed an immune suppressive GREVAX vector that allows the veto engineering of any transplant. The GRECD8™ vector selectively eliminates immune responses against the transplant without inhibiting its protective functions.